Epitheliotropic cutaneous lymphoma with mucocutaneous characteristics in a Yorkshire Terrier: case report
DOI:
https://doi.org/10.26605/medvet-v19n2-7055Keywords:
depigmentation, immunohistochemistry, mucous membranes, oncologyAbstract
Cutaneous lymphoma is a lymphoid tumor characterized by the clonal proliferation of neoplastic lymphoid cells in the superficial or deep strata of the skin. From the histological examination, depending on the tropism of the neoplastic cells in relation to the epithelium, it can be classified into epitheliotropic cutaneous lymphoma and non-epitheliotropic cutaneous lymphoma, with the epitheliotropic form being the most prevalent. The disease has a malignant, progressive character and particular clinical signs: serpiginous and erythematous skin lesions, focal or disseminated, in addition to being able to have an atypical presentation, with lesions focally on the mucous membranes. Diagnosis in dogs involves the patient's clinical history, laboratory, cytological, histopathological and immunohistochemical tests of the tumor tissue. Chemotherapy emerges as the most appropriate therapeutic modality, however, surgical treatment, radiotherapy, or both, can also be used as a complement to treat cases with localized presentations. Given the aggressive and difficult-to-control course of the pathology, the prognosis is considered unfavorable.Downloads
References
Aslan, J.; Shipstone, M.A.; Sullivan, L.M. Treatment of canine cutaneous epitheliotropic T-cell lymphoma with oclacitinib: a case report. Veterinary Dermatology, 32(4): 398, 2021.
Bernabe, L.F. et al. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Veterinary, 9(190): 1-10, 2013.
Chan, C.M.; Frimberger, A.E.; Moore, A.S. Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003–2015). Veterinary Dermatology, 29(2): 154-159, 2018.
Daleck, C.R.; De Nardi, A.B. Oncologia em cães e gatos. 2a ed. Rio de Janeiro: Roca, 2016. 766p.
De Lorimier, L. P. Updates on the management of canine epitheliotropic cutaneous T-cell lymphoma. Veterinary Clinics - Small animal practice, 36(1): 213-228, 2006.
Dettwiler, M. et al. Prognostic clinical and histopathological features of canine cutaneous epitheliotropic T-cell lymphoma. Veterinary Pathology, 60(2): 162–171, 2023.
Fontaine, J. et al. Canine cutaneous epitheliotropic T-cell lymphoma: a review. Veterinary and Comparative Oncology, 7(1): 1-14, 2009.
Kristal, O. et al. Hepatotoxicity associated with CCNU (Lomustine) chemotherapy in dogs. Journal of Veterinary Internal Medicine, 18(1): 75-80, 2004.
Laprais, A.; Olivry, T. Is CCNU (lomustine) valuable for treatment of cutaneous epitheliotropic lymphoma in dogs? A critically appraised topic. BioMed Central Veterinary Research, 13(1): 61, 2017.
Mazaro, R.D. et al. Epidemiological, anatomopathological, and immunophenotypical aspects of cutaneous lymphomas in dogs. Pesquisa Veterinária Brasileira, 43(07124): 1–16, 2023.
Miller, W.H.; Griffin, C.E.; Campbell, K. Tumors of lymphoid Origem. In: Muller and Kirk’s small animal dermatology. 7th ed. Philadelphia: W.B. Saunders, 2013. p. 810-840.
Nelson, R.W.; Couto, G.C. Medicina interna de pequenos animais. 5ª ed. Rio de Janeiro: Elsevier, 2015. 1512p.
Risbon, R.E. et al. Response of Canine Cutaneous Epitheliotropic Lymphoma to Lomustine (CCNU): a retrospective study of 46 dogs (1999-2004). Journal of Veterinary Internal Medicine, 20(6): 1389–1397, 2006.
Rook, K.A. Canine and feline cutaneous epitheliotropic lymphoma and cutaneous lymphocytosis. The Veterinary Clinics of North America: Small Animal Practice, 49(1): 67–81, 2019.
Souza, T.M. et al. Estudo retrospectivo de 761 tumores cutâneos em cães. Ciência Rural, 36(2): 555-560, 2006.
Valli, V.E.O. et al. Classification of canine malignant lymphomas according to the World Health Organization criteria. Veterinary Pathology, 48(1): 198-211, 2011.
Valli, V.E.O. et al. Pathology of domestic animals. 6th ed. St. Louis: Elsevier, 2016. p.102-268.
Yancey, M.F. et al. Distribution, metabolism, and excretion of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics, 33: 154–161, 2010.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Isabela Gilena Lins dos Santos, Ivina de Almeida Freitas, Lilian Sabrina Silvestre de Andrade, Luana Mirela de Sales Pontes, Roana Cecília dos Santos Ribeiro
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
A Revista de Medicina Veterinária permite que o autor retenha os direitos de publicação sem restrições, utilizando para tal a licença Creative Commons CC BY-NC-SA 4.0.
De acordo com os termos seguintes:
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
NãoComercial — Você não pode usar o material para fins comerciais.
CompartilhaIgual — Se você remixar, transformar, ou criar a partir do material, tem de distribuir as suas contribuições sob a mesma licença que o original.
Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
